A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age
Latest Information Update: 30 Jun 2023
At a glance
- Drugs PXVX 0200 (Primary)
- Indications Cholera
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic; Emergent BioSolutions; PaxVax
- 12 Mar 2023 Results published in the Vaccine
- 27 Oct 2020 Status changed from active, no longer recruiting to completed.
- 01 Jan 2020 According to results published in the American Journal of Tropical Medicine and Hygiene, recruitment in cohort 1 and cohort 2 of the trial has been completed.